CLINICAL-DIAGNOSTIC FEATURES AND MODERN TREATMENT PRINCIPLES OF MENSTRUAL CYCLE DISORDERS IN WOMEN OF REPRODUCTIVE AGE

Authors

  • Ubaydullayeva Shinar Azimbayevna Samarkand State Medical University, Samarkand, Uzbekistan Author
  • Axtamova Nilufar Akbarjanovna Samarkand State Medical University, Samarkand, Uzbekistan Author

Keywords:

menstrual cycle disorders, reproductive endocrinology, hypothalamic-pituitary-ovarian axis, Polycystic Ovary Syndrome (PCOS), insulin resistance, targeted therapy, ovulatory dysfunction, hyperandrogenism.

Abstract

Menstrual cycle disorders among women of reproductive age represent a multifaceted gynecological, endocrine, and metabolic challenge. These irregularities—ranging from oligomenorrhea and amenorrhea to abnormal uterine bleeding—are primary contributors to female infertility, metabolic syndrome, and significant reductions in overall quality of life. Despite the high prevalence of these conditions, traditional therapeutic paradigms have often relied heavily on symptom management rather than addressing the root pathophysiological causes.

References

1.ACOG Committee on Practice Bulletins—Gynecology. (2022). Management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstetrics & Gynecology, 122(1), 176–185.

2.Speroff, L., & Fritz, M. A. (2020). Clinical Gynecologic Endocrinology and Infertility (9th ed.). Lippincott Williams & Wilkins.

3.Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., ... & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1), 1-18.

4.Fraser, I. S., Critchley, H. O., Broder, M., & Munro, M. G. (2018). The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Seminars in Reproductive Medicine, 29(5), 383-390.

5.Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., ... & Yildiz, B. O. (2023). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602-1618.

6.Chrousos, G. P., & Kino, T. (2020). Glucocorticoid signaling in the cell: Expanding clinical implications to complex human physiologic and pathologic conditions. Annals of the New York Academy of Sciences, 1179, 153–166.

7.Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2021). Polycystic ovary syndrome. The Lancet, 370(9588), 685-697.

8.Diamanti-Kandarakis, E., & Dunaif, A. (2019). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33(6), 981-1030.

9.Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., ... & Simoncini, T. (2019). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 28(12), 969-973.

Downloads

Published

2026-05-26